Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

insulin glargine (HOE901)

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

insulin glargine- new formulation (HOE901)

Pharmaceutical form: solution Route of administration: subcutaneous

Trial Locations (1)

Investigational Site Number 392001, Kumamoto